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Background: Surgical site infections (SSIs) are the second most common form of nosocomial infection. Colorectal
resections have high rates of SSIs secondary to the inherently contaminated intraluminal environment. Negative
pressure wound therapy dressings have been used on primarily closed incisions to reduce surgical site infections in
other surgical disciplines. No randomized control trials exist to support the use of negative pressure wound therapy
following elective open colorectal resection to reduce surgical site infection.
Methods/Design: In this single-center, superiority designed prospective randomized open blinded endpoint
controlled trial, patients scheduled for a colorectal resection via a laparotomy will be considered eligible. Patients
undergoing laparoscopic resection will be enrolled but only randomized and included if the operation is converted to
an open procedure. Exclusion criteria are patients receiving an abdominoperineal resection or a palliative procedure, as
well as pregnant patients and those with an adhesive allergy. After informed consent, 300 patients will be randomized
to the use of a standard adhesive gauze dressing or to a negative pressure wound device. Patients will be
followed in hospital and reassessed on post-operative day 30. The primary outcome measure is SSI within the
first 30 post-operative days. Secondary outcomes include the length of hospital stay, the number of return visits
related to a potential or actual SSI, cost, and the need for homecare. The primary endpoint analysis follows the
intention-to-treat principle.
Discussion: NEPTUNE is the first randomized controlled trial to investigate the role of incisional negative
pressure wound therapy in decreasing the rates of surgical site infections in the abdominal incisions of patients
following an elective, open colorectal resection. This low-risk intervention may help decrease the morbidity and
costs associated with the development of an SSI in our patients.
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Surgical site infections (SSIs) are the second most com-
mon type of nosocomial infection and represent a sig-
nificant burden on the healthcare system [1, 2]. The
morbidity, increased length of stay, delay in further
treatment (adjuvant chemotherapy or radiation) as well
as the significant psychological effects on patients has
been well demonstrated in the literature [3, 4]. In 1998,
the only cost-analysis related to SSI that was performed
in a Canadian center was published. Here, Zoutman and
colleagues demonstrated an average of US$4000 in
additional costs per patient [5]. Resections of colonic
and rectal segments have been associated with the
highest rates of SSI amongst cases without perforation
of gross intra-abdominal contamination, likely secondary
to the inherently contaminated intra-luminal environment
[6]. In such circumstances, despite best practice recom-
mendations of pre-operative antibiotic use and aseptic
operative technique [4], SSIs are reported at rates of 15
to 30 % [7, 8].
Few interventions beyond pre-operative antibiotic
prophylaxis and aseptic technique have been shown to
decrease rates of SSI. Negative pressure wound therapy
(NPWT) is a relatively new treatment concept, initially
reported on in 1997 by Morykwas et al. as a novel therapy
for chronic wounds [9].
The first identifiable report in the literature on incisional
NPWT (iNPWT) is a case-series from Gomoll et al. in the
setting of orthopedic trauma. They demonstrated a de-
crease in serous exudative rates and good healing of inci-
sions post-operatively [10]. Cardiac surgery patients are
known to be susceptible to mediastinitis, associated with
significant morbidity and mortality. A retrospective review
of 57 such patients who received iNPWT was reported in
2009 whereby an absence of any sternal wound infections
was demonstrated [11]. In 2011, Stannard randomized 263
blunt orthopedic trauma patients with high-risk tibial and
calcaneal fractures requiring surgical stabilization to either
usual care or iNPWT [12]. Here they demonstrated a rela-
tive risk of infection of 1.9 times higher in control patients
with no significant difference in the injury severity scores
of each group. In a recently published series, 27 patients,
postabdominoperineal resection, with significant risk
factors for wound infection had iNPWT applied to their
perineal incisions until the fifth post-operative day [13].
When compared to a recent historical control group, a
statistically lower rate of perineal SSI was detected in
the intervention group. Furthermore, on multivariate
analysis, when other risk factors were controlled for,
the use of iNPWT was found to be protective against
the outcome of perineal SSI. Finally, Matatov et al. per-
formed a retrospective cohort study using the same
NPWT dressing as the current proposal and found a sig-
nificant difference (24 % versus 6 %) in SSI compared tostandard dressing following 115 femoral cut-downs for
vascular procedures [14].
Patients undergoing elective, open colorectal surgery are
at a high risk of SSI. Given the significant patient morbidity
associated with this complication, there is an identifiable
need for an intervention to help decrease the rates of SSI
in this patient population. Furthermore, there is a paucity
of literature investigating the role of iNPWT in colorectal
surgery. The objective of this study is to assess the role of
iNPWT in patients undergoing an elective, open colorectal
resection (CRR) on decreasing the rates of SSI as compared
with a standard gauze adhesive dressing. We hypothesize
that patients randomized to iNPWT will have a lower inci-
dence of SSI within the first 30 days of surgery compared
to patients randomized to the control group. The trial will
be a prospective, randomized, superiority trial.
Methods/Design
A prospective analysis of SSIs at our institution was done
to prepare the calculation of power and sample size, and
informed the trial protocol and manuscript creation. Our
institutional ethics at the University of Western Ontario
performed a Full-Board review and approved the trial (REB
104819). The trial is registered at Clinicaltrials.gov
(NCT02007018). This protocol conforms to SPIRIT recom-
mendations for the minimum set of scientific, ethical, and
administrative elements that should be addressed in a clini-
cal trial protocol (Additional file 1). Financing is granted
through an industry grant with Kinetic Concepts Inc. (San
Antonio, TX, USA). The study sponsor has no role in data
collection, management, analysis, writing or influence on
the decision to publish results.
Study design
This is a single-institution, prospective, randomized, open
label, blind endpoint trial design [15] with a superiority
framework, in which eligible patients will be randomized
to iNPWT or a standard gauze adhesive dressing using
block randomization and stratification based on one of two
hospital sites.
Study setting
The study will take place at the two campuses of London
Health Sciences Center (LHSC) in London, Ontario,
Canada: University Hospital and Victoria Hospital. Both
hospitals are academic teaching hospitals and are associ-
ated with the Schulich School of Medicine and Dentistry
at Western University. Both sites use an enhanced recov-
ery after surgery protocol following colorectal surgery to
improve patient outcomes and reduce length of stay [16].
Eligibility
Patients scheduled for any elective CRR requiring a mid-
line laparotomy are potentially eligible for the study.
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to be enrolled but will only be randomized and included
if their surgical procedures are converted to open
through a midline laparotomy. Eligible surgical proce-
dures include segmental, sub-total or total colectomies
as well as low and ultra-low anterior resections. Before
enrollment informed consent will be obtained from each
patient. Patients will be identified by study personnel
and will be enrolled from the pre-operative clinic by a
study nurse.
Inclusion criteria
Patients must be 18 years or older and scheduled for an
elective CRR and must undergo an open procedure or
laparoscopic procedure converted to open operation.
Informed consent must be obtained.
Exclusion criteria
Patient who undergo abdominoperineal resections and
pelvic exenterations, or have a bowel perforation at the
time of operation will be excluded. Patients undergoing an
operation for palliative purposes (life expectancy less than
3 months), who are pregnant, or who have a known sensi-
tivity/allergy to adhesive material will also be excluded.
Intervention and control
The intervention addresses the type of dressing applied fol-
lowing an elective, open, colorectal operation. The interven-
tion is iNPWT in the form of the Prevena™ Incision
Management System (PIMS) (Kinetic Concepts Inc. (KCI),
San Antonio, TX, USA). This is a sponge dressing connected
to a hand-held continuous vacuum in a single-use unit. The
vacuum is set to 125 mm Hg. The device is applied under
sterile conditions in the operating theater and remains on
the patient until the earlier of post-operative day 5 or hos-
pital discharge. Any concern about the wound or the device
will require removal of the iNPWT earlier than planned, and
will be recorded as a secondary endpoint of the trial.
The control dressing is a gauze adhesive dressing which
covers the laparotomy incision. The post-operative man-
agement is typically removal on day 2 post-operatively
with daily dressing changes thereafter. Apart from the
dressing applied to the wound in the operating room, and
the care of that dressing post-operatively, the patients pre-
and post-operative care will be the same in both groups.
As per current best practice in SSI prevention, the follow-
ing regimen will be applied to all trial patients, regardless of
intervention arm. A standardized dose of pre-operative anti-
biotics (depending on allergy status) directed by the hospital’s
local antibiogram will be administered to patients within
30 minutes prior to surgery, and will be re-dosed in proce-
dures longer than 4 hours. Post-operative antibiotics will be
allowed for a maximum of 24 hours. Hair will be removed
with electric clippers. Skin preparation will be performedwith 2 % chlorhexidine unless the patient has an allergy to
this preparation.
Randomization, allocation concealment and blinding
Randomization will take place centrally using random per-
mutated blocks of 4, 6 or 8 and will be stratified based on
site (University Hospital or Victoria Hospital) of the oper-
ation. After the fascia is closed a member of the surgical
team will use a centralized web-server to randomize the
patient. The surgical team, clinical staff, and patient will not
be blinded to the intervention status. The primary outcome
of SSI will, however, be blinded to the outcome assessors, as
the dressing (iNPWT or adhesive gauze) will be removed by
the clinical team prior to the first visit from the outcome
assessors on post-operative day 5 or the day of hospital
discharge. The outcome assessors are blinded and will assess
the wound daily after the dressing is removed until hospital
discharge. A minority of wounds are expected to be seen by
the on-call team and it is unlikely the resident or physician
involved will know the patient’s treatment allocation.
Definition of endpoints and outcome measures
The primary endpoint is the incidence of SSI within
30 days of surgery. SSI is defined by the Center for Disease
Control and Prevention (CDC) criteria [1] as: infection
occurring within the first 30 post-operative days with at
least one of the following:
1. Purulent drainage from the incision
2. Organisms isolated from an aseptically obtained
culture of fluid or tissue from the incision
3. At least one of the following signs/symptoms of
infection:




In these instances, the incision is deliberately opened
by a surgeon (unless the incision is culture negative)
4. Diagnosis of SSI by the surgeon or attending
physician.
SSI will be assessed every day following dressing re-
moval, at discharge, 30 days following the operation or
at any time during the study period if the patient or
surgical team has concerns about the development of
an SSI in the laparotomy incision.
Secondary endpoints
Secondary outcomes assessed will include the need for, and
duration of at-home nursing care (home care) related to SSI.
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team after the identification of an SSI. The duration of home
care requirements will be determined at the time of post-
operative clinic visits, and by contact with the home care
provider. Additional secondary outcomes assessed will in-
clude the length of hospital stay, the number of return visits
related to a potential or actual SSI, and cost. The cost will
be determined based on the average cost provided by LHSC
for inpatient, emergency department (ED) or clinic care, and
billing fees for both the surgeon and anesthetist for any re-
turn trip to the operating room. Standardized time and ma-
terials costs will be obtained using available data from the
Community Care Access Center for home care. A return
visit related to an SSI will include any visit to the ED, out-
patient surgical clinic, or requirement for admission to
hospital that is deemed by the primary surgeon or study
team to be due to a) signs or symptoms of SSI requiring
assessment; b) development of an SSI requiring manage-
ment; or c) ongoing care of a known SSI. The manage-
ment cost of an SSI will be calculated for each instance.
Outcomes related to potential harm will also be identified
including local reaction to the iNPWT device, and the
need for early removal of the dressing.
Sample size
Our pilot study revealed an SSI rate of 35 % in patients
undergoing colorectal surgery at our institution. Based
on previous studies and the clinical experience of the
study’s senior investigators, a reduction in the rate of SSI
to 20 % (absolute risk reduction 15 %; relative risk re-
duction 43 %) may be expected. This is the minimum
clinically relevant reduction both from a patient out-
come perspective and a cost reduction standpoint. Given
an alpha of 0.05, for 80 % power, this yields a required
sample size of 138 patients per group. The planned sam-
ple size will be inflated for potential loss of follow-up,
and will be rounded for a final sample size of 150 pa-
tients per group and a total study sample of 300 patients.
Loss to follow-up is felt to be a minimal concern as pa-
tients are required to attend their 30-day post-operative
visit to maintain the therapeutic relationship with the
surgeon for oncological and disease management.
Data collection and management
All data collected (baseline characteristics, primary and
secondary outcomes) will be recorded through an online
data collection portal and be maintained behind a secure
server and firewall. Data will be collected by the study
nurse, trial personnel and surgical teams. A Data Safety
and Monitoring Board (DSMB) will be assembled con-
sisting of three surgeons not involved in patient accrual
or in study administration. Given previous demonstra-
tion of the safety of iNPWT, we expect minimal to no
harm. Accuracy of data collection through the onlinesecure data collection forms will be ensured by the DSMB
by performing sample assessments at regular intervals.
The severity of adverse events will be evaluated using
the Common Terminology Criteria for Adverse Events
(CTCAE) v4.0 grading scale (see http://ctep.cancer.gov).
Any grade 4 or grade 5 events will be reported to the
primary investigator, the DSMB, and the institutional
research ethics board as well as the device company
headquarters through established reporting systems.
Statistical analysis
All analysis will be pre-specified and conducted accord-
ing to the intention-to-treat principle with the use of
SPSS version 20 (SPSS Inc., Chicago, IL, USA). The pro-
portion of SSIs amongst all patients undergoing CRR
will be compared between the iNPWT and adhesive
gauze arms using a chi-square test. An absolute risk in-
crease/reduction for SSI will be presented for the use of
iNPWT, as well as the number needed to treat to pre-
vent a single SSI. Data will be analyzed according to the
intention-to-treat principle. Patients lost to follow-up
will be considered to have developed an SSI for the pur-
poses of primary analysis. Furthermore, despite instruc-
tions to contact or return to clinic if any concerns of an
SSI arise, any incisions diagnosed or treated for an SSI by
any physician will be considered as having had an SSI.
Baseline characteristics of the two groups will be re-
corded, including body mass index (BMI), self-reported
smoking status and co-morbidities. In the event that any
of the baseline characteristics are found to differ signifi-
cantly between the intervention and standard care
groups by chance, secondary analyses will be performed
using multivariable logistic regression to adjust for the
effect of differences in the baseline characteristics on the
primary outcome. Results will then be presented as an
adjusted odds ratio.
Secondary outcomes will be compared between groups
using a chi-square for categorical variables (i.e., need for
home care, proportion receiving antibiotics). Non-normally
distributed continuous variables (length of hospital stay,
duration of home care treatment, number of return visits)
will be compared using the Mann-Whitney U-test. As po-
tential harm is expected to be minimal, incidence of al-
lergy/sensitivity to iNPWT will be reported, but no formal
statistical analyses are planned. A pvalue of less than 0.05
will be considered significant. The trial will undergo only
one set of analyses at trial completion. No interim monitor-
ing is planned as, given the small sample size, any interim
analysis would have too few events to be interpreted. Re-
cruitment will be completed over 12–16 months, and given
that the primary outcome has occurred by 30 days after the
last patient is randomized, primary outcome assessment
will have occurred by 18 months. Allowing for prolonged
data collection for up to 3 months for secondary outcomes,
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after the trial commences.
Discussion
The NEPTUNE trial is the first randomized controlled
trial to investigate the role of iNPWT in reducing the
incidence of SSIs in elective, open, CRR. Only one
other study has been performed investigating the role
of iNPWT following a CRR using a retrospective cohort
design. Bonds et al., used iNPWT in patients following
a CRR, at the request of the operating surgeon [17]. Al-
though no difference was reported on univariate ana-
lysis, the use of iNPWT was found to be protective for
SSI on multivariate analysis after controlling for various
risk factors. Despite the positive findings and adjust-
ments made, a significant selection bias exists in this
study, and a randomized controlled trial is warranted.
It is anticipated that the NEPTUNE trial will assist in
the development of consensus recommendations for
the use of iNPWT in patients following a CRR.
There are multiple theorized benefits of iNPWT in de-
creasing SSI rates. In a study by Wackenfors et al., laser
Doppler velocimetry was used to assess the vascularity
of incisions in a porcine model with NPWT. Increases in
tissue microvascular perfusion were seen to correlate
with the pressure applied in addition to increases in the
partial pressure of oxygen within the soft tissue environ-
ment [18]. Other porcine models have demonstrated re-
duced rates of hematoma and serum formation in
addition to increased lymphatic fluid clearance [19]. This
is also associated with decreased shear forces and
stresses as the negative pressure environment maintains
tissue apposition. Incisional NPWT devices decrease the
lateral stresses placed on incisions by approximately
50 %, leading to a distribution more consistent with that
of intact tissue and further increases the force required
to disrupt the incision [20]. The closed suction environ-
ment placed under sterile conditions also effectively
separates the incision from the surrounding environment,
thus theoretically preventing the inoculation of environ-
mental bacteria.
This design of this trial will allow for strong conclu-
sions to be made as to the role of iNPWT after CRR.
The major limitation of this trial is in the inability to
completely blind members of the clinical team, and the
patient, to the treatment arm. Placebo control is not
felt to be possible, as any additional dressing placed
over the surgical wound may alter wound healing me-
chanics, and, therefore, likely impact on the rate of SSI.
The idea of a “sham device” was initially entertained,
but given the pragmatic nature of this trial, this or any
alternate dressing would further fail to represent the
current standard of care and use may result in misleading
conclusions.The results of this trial will be used to determine the
role of iNPWT in the prevention of SSI after colorectal
surgery. If this intervention is shown to be effective for the
prevention of SSI in this high-risk population, significant
benefit with respect to both patient morbidity and re-
source utilization may be achieved.
Trial status
Enrollment started on 5 January 2015.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist in word document (.doc)
format. The SPIRIT Checklist provides recommendations for the
minimum set of scientific, ethical and administrative elements that
should be addressed in a clinical trial protocol.
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